For many years, scientists have tried – and failed – to develop techniques to activate the body’s immune system
“It’s a matter of economics” says the bar manager in the film The Fabulous Baker Boys when they get paid off and realize two piano players are no longer enough and they need to find a singer.
Last week saw the release of the majority of the abstracts for the 2013 European Cancer Congress that takes place at the RAI conference center in Amsterdam from September 27 to October 1st (Twitter hashtag #ECC2013). Not yet available are the late-breakers and those abstracts included in the media press conference program.
Earlier this month, Janssen/Pharmacyclics announced they had submitted a New Drug Application (NDA) for Food & Drug Administration (FDA) approval
Takeda’s orteronel (formerly known as TAK-700) may be on its way to “dog drug heaven” after an interim
Johnson & Johnson (JNJ) just announced the acquisition of privately-held Aragon Pharmaceuticals and the rights to ARN-509 a
At ASCO 2013 Daniel D. Van Hoff, MD, Physician-In-Chief of the Translational Genomics Research Institute (TGen), presented the data for the
AZD3514 is a novel Selective Androgen Receptor Down-Regulating Drug (SARD) that showed early preclinical promise for the treatment of Castration-Resistant Prostate Cancer (CRPC).